Generic of Sensipar: US court denies Amgen request for preliminary injunction against Cipla

Cipla's cinacalcet hydrochloride tablets in the strengths of 30mg, 60mg and 90mg are generic versions of Sensipar, a branded drug marketed by Amgen Inc.

New Delhi: Pharma major Cipla Friday said the US District Court of Delaware has denied Amgen Inc's request for a preliminary injunction to stop Cipla's continued sale of its generic cinacalcet hydrochloride tablets in the US market.

The preliminary injunction is a court order made in the early stages of a lawsuit that prohibits the parties from doing an act in order to preserve the status quo until the trial is over and the court has issued a ruling or judgment.

Read Also:Cipla gets USFDA nod for Ambrisentan tablets to treat pulmonary arterial hypertension

The company had announced a phased launch of generic cinacalcet hydrochloride tablets, used in the treatment of secondary hyperparathyroidism in adult patients with chronic kidney disease on dialysis, in the US market in a regulatory filing in March this year.

The launch, however, is a subject of ongoing litigation, it had added.

Read Also: Dr Reddys, Cipla arm recall drugs in US; includes 7.8 lakh vials of Testosterone Cypionate injection

"... Chief Judge Stark of the US District Court of Delaware denied Amgen, Inc's request for a preliminary injunction to stop Cipla's continued sale of its generic cinacalcet hydrochloride tablets 30mg, 60mg, 90mg in the USA," Cipla said in a filing to BSE.

Cipla's cinacalcet hydrochloride tablets in the strengths of 30mg, 60mg and 90mg are generic versions of Sensipar, a branded drug marketed by Amgen Inc.

Read Also: Cipla appoints Dr Raju Mistry as Global Chief People Officer